Since the outset of the COVID-19 pandemic, numerous risk factors for severe disease have
been identified. Whether patients with rheumatic diseases, especially those receiving …

Objectives COVID-19 outcomes in people with rheumatic diseases remain poorly understood.
The aim was to examine demographic and clinical factors associated with COVID-19 …

PURPOSE: Randomized controlled trials (RCTs) have demonstrated the efficacy of biologic
agents in the treatment of rheumatic diseases. However, results from RCTs may not be …

Juvenile idiopathic arthritis (JIA) is an umbrella term for arthritis of unknown origin, lasting for
>6 weeks with onset before 16 years of age. JIA is the most common chronic inflammatory …

Patient-reported outcomes (PROs) reflect the patient’s perspective and are used in rheumatoid
arthritis (RA) routine clinical practice. Patient global assessment (PGA) is one of the most …

Objectives To determine factors associated with COVID-19-related death in people with
rheumatic diseases. Methods Physician-reported registry of adults with rheumatic disease and …

Objectives. To evaluate the risk of serious infections (SIs) in patients with RA treated with
anti-TNF therapy with emphasis on the risk across different ages. Methods. Using data from the …

Objective Patients with rheumatoid arthritis (RA) who experience treatment failure with one
anti–tumor necrosis factor (anti‐TNF) agent, due to either inefficacy or toxicity, are frequently …

Background Despite treatment according to the current management recommendations, a
significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These …

Objectives To provide an update of the EULAR rheumatoid arthritis (RA) management
recommendations addressing the most recent developments in the field. Methods An international …